BEVERLY, MA – November 1, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent & Trademark Office recently announced the allowance of another application directed to Brilacidin.
The “Notice of Allowance” is directed to Brilacidin oral, buccal, and sublingual pharmaceutical compositions. The allowed claims for Brilacidin pharmaceutical compositions include liquid compositions, such as rinses. Previously issued U.S. Patents for Brilacidin include U.S. Patent Numbers: 8,802,683; 9,155,738; 9,457,027; and 9,795,575.
“These new patent protections further bolster the intellectual property estate that we’ve built around Brilacidin, our novel Host Defense Protein mimetic drug candidate,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “The new allowances are of particular relevance to Brilacidin for the treatment of oral mucositis, in head and neck cancer patients, administered as a convenient oral rinse. The Company currently is preparing for an End-of-Phase 2 meeting with the FDA to discuss Brilacidin oral rinse continued development in addressing this area of large unmet need. Future clinical applications of Brilacidin in liquid form to treat other indications may potentially include chronic sinusitis and infections related to periodontal disease.”